News & Videos - SYNCONA LIMITED ORD NPV

LONDON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (“Freeline”) and Syncona Ltd (“Syncona”) today announced that, in connection with Syncona’s acquisition of Freeline by way of a scheme of arrangement (the “Scheme”), the Scheme has been sanctioned by the Court and the court order (together with a copy of the scheme circular published by Freeline on January 18, 2024 (the “Scheme Circular”) has been delivered to the Registrar of Companies....

LONDON, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (“Freeline”) and Syncona Ltd (“Syncona”) today announced that Freeline’s shareholders have approved the proposal for Bidco 1354 Limited (“Bidco”), a wholly owned subsidiary of Syncona Portfolio Limited (“Syncona Portfolio”), to acquire all shares of Freeline not currently owned by Syncona Portfolio for $6.50 per American Depositary Share (“ADS”) in cash (the “Acquisition”). As...

Freeline shareholders to receive $6.50 per American Depositary Share, a 51% premium over closing price prior to announcement of Syncona’s initial proposal on October 18, in an all-cash transaction Based on extensive evaluation of available strategic and financing options, Freeline’s independent directors unanimously recommend transaction as best value for shareholders Syncona to provide $15 million in convertible debt financing to cover Freeline’s near-term capital needs and support...

Syncona Limited - Issue of shares pursuant to the Long Term Incentive Plan PR Newswire London, August 13 Syncona Limited Issue of shares pursuant to the Long Term Incentive Plan 13 August 2018 Syncona Limited (the "Company") today announces that a total of 20,836 new ordinary shares will be issued in satisfaction of realisations under the Company’s Long Term Incentive Plan. The new ordinary shares, when issued, will rank pari passu with the existing issued ordinary shares of the Company. In...

Syncona Limited - Nightstar reports Q2 2018 financial results PR Newswire London, August 13 Syncona Limited Nightstar reports Q2 2018 financial results 13 August 2018 Syncona Ltd, a leading healthcare company focused on investing in and building global leaders in life science, notes the announcement that its portfolio company, Nightstar Therapeutics Plc (NASDAQ: NITE) (Nightstar), reported its Second Quarter 2018 Financial Results today, 13 August 2018 . The announcement can be accessed on...

Syncona Limited - Syncona Limited Quarterly Update PR Newswire London, August 8 Syncona Limited Quarterly Update 9 August 2018 Syncona Ltd, a leading healthcare company focused on investing in and building global leaders in life science, today issues its quarterly update covering the period from 1 April 2018 to 30 June 2018 . Financial and Operational highlights for the three months ending 30 June Net assets increased to £1,283.2 million, 193.1p per share[1], a total return of 23.0 per cent[2]...

Syncona Limited - PDMR Dealing PR Newswire London, August 2 Syncona Limited Notification of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs") and Connected Persons 2 August 2018 1. Details of PDMR / person closely associated with them ("PCA") a) Name Martin Murphy b) Position / status Chief Executive Officer, SIML c) Initial notification / amendment Initial Notification 2. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each...

Syncona Limited - Results of AGM PR Newswire London, July 31 Syncona Limited Result of Annual General Meeting 31 July 2018 At the Annual General Meeting (“AGM”) of the Company held today, all Resolutions as set out in the Notice of AGM dated 27 June 2018 sent to shareholders of the Company (the “Notice”) were duly passed. Resolutions 1 to 13 were proposed as ordinary resolutions. Only shareholders who were “Independent Shareholders” as such term is defined in the Notice were entitled...

Syncona Limited - Directors Dealings PR Newswire London, July 30 Syncona Limited Notification of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs") and Connected Persons 30 July 2018 1. Details of PDMR / person closely associated with them ("PCA") a) Name Jeremy Tigue b) Position / status Chairman c) Initial notification / amendment Initial Notification 2. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction;...

Syncona Limited - Issue of shares pursuant to the 2018 dividend PR Newswire London, July 25 Syncona Limited Issue of shares pursuant to the 2018 dividend 25 July 2018 Syncona Limited (the "Company") today announces that a total of 1,249,383 new ordinary shares will be issued in satisfaction of the payment of the Company’s 2018 dividend to those qualifying shareholders who did not elect to receive the dividend in cash. The new ordinary shares, when issued, will rank pari passu with the existing...

Syncona Limited - 2018 Dividend Scrip Reference Price PR Newswire London, June 29 Syncona Limited 2018 Dividend Scrip Reference Price 29 June 2018 Syncona Limited announces that the scrip reference price for its 2018 dividend will be £2.418. This is the higher of (i) the prevailing average of the middle market quotations of its ordinary shares derived from the Daily Official List of the London Stock Exchange for the ex-dividend date, 21 June 2018 , and the four subsequent dealing days and (ii)...

Syncona Limited - Monthly Factsheet - May 2018 PR Newswire London, June 29 Syncona Limited (a closed-ended investment company incorporated in Guernsey with registration number 55514) Monthly Fact Sheet May 2018 Attached is a link to the May 2018 Monthly Fact Sheet for Syncona Limited. http://content.prnewswire.com/documents/PRNUK-2906181014-94B1_Syncona_May_Factsheet_CC.pdf Enquiries: Fraser Hiddelston Northern Trust International Fund Administration Services (Guernsey) Limited Tel: +44 (0) 1481...

Syncona Limited - Publication of 2018 Annual Report and Notice of AGM PR Newswire London, June 26 Syncona Limited Publication of 2018 Annual Report and Notice of Annual General Meeting 27 June 2018 Syncona Limited (“Syncona”), a leading healthcare company focused on investing in and building global leaders in life science, today announces that it has published its Annual Report and Accounts for the year ended 31 March 2018 (“2018 Annual Report”). In addition, Syncona has published its...

Syncona Limited - Autolus closes IPO PR Newswire London, June 26 Syncona Limited Autolus closes IPO LONDON , 26 June 2018 Syncona Ltd, a leading healthcare company focused on investing in and building global leaders in life science notes that its portfolio company Autolus Therapeutics plc (“Autolus”) has announced the closing of its previously announced initial public offering (“IPO”) in the United States of 10,147,059 American Depositary Shares ("ADSs"), representing 10,147,059 ordinary...

Syncona Limited - Autolus update on IPO PR Newswire London, June 22 Syncona Limited Autolus update on IPO 22 June 2018 · Second Syncona founded business to IPO, four years after Autolus incorporated · Autolus well positioned to develop next generation T cell therapies which have the potential to be best-in-class and offer cancer patients substantial benefits over the existing standards of care · Increase in value of Syncona’s current shareholding of £69.6 million (10.5p per share)[1] to...

Syncona Limited - Syncona makes £85 million commitment to Freeline PR Newswire London, June 18 Syncona Limited SYNCONA MAKES £85 MILLION COMMITMENT TO FREELINE 19 June 2018 Significant £85 million backing for clinical stage Syncona-founded AAV gene therapy company Commitment takes Syncona’s life science portfolio over 50 per cent of net assets[1] Syncona Ltd, a leading healthcare company focused on investing in and building global leaders in life science, today announces that it has...

Syncona Limited - Nightstar receives RMAT designation in Choroideremia PR Newswire London, June 14 Syncona Limited Nightstar receives RMAT designation in Choroideremia 14 June 2018 Syncona Ltd, a leading healthcare company focused on investing in and building global leaders in life science, today notes that its portfolio company, Nightstar Therapeutics Plc (NASDAQ: NITE) (Nightstar), has announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy...

Syncona Limited - Syncona Limited Full Year Results 2018 PR Newswire London, June 13 14 June 2018 Syncona Limited Final Results for the Year Ended 31 March 2018 Syncona invests in innovative areas of healthcare, taking a long-term view and a significant ownership stake while working in deep partnership with our companies to build global leaders in life science. Strong returns and NAV increase with positive performance across the Company in the year Net assets at year end of £1,055.8 million,...

Syncona Limited - Update on Autolus proposed IPO in the United States PR Newswire London, June 8 Syncona Limited Update on Autolus proposed IPO in the United States 8 June 2018 Syncona Ltd, a leading healthcare company focused on investing in and building global leaders in life science, today notes that its portfolio company Autolus Therapeutics Limited (to be reorganised as Autolus Therapeutics plc) (“Autolus”) has filed an amended registration statement on Form F-1 with the U.S. Securities...

Syncona Limited - Nightstar reports Q1 Financial Results PR Newswire London, June 6 Syncona Limited Nightstar reports Q1 2018 financial results 6 June 2018 Syncona Ltd, a leading healthcare company focused on investing in and building global leaders in life science, today notes the announcement that its portfolio company, Nightstar Therapeutics Plc (NASDAQ: NITE) (Nightstar), reported its First Quarter 2018 Financial Results today, 6 June 2018 . The announcement can be accessed on Nightstar’s...